Hummingbird Bioscience has announced that it will use its new investment to accelerate the development of clinical trials and strengthen its scientific research and development capabilities.
South Korean SK Holdings, whose name we recently heard in the public offering news of n11.com, invested in Singapore-based health venture Hummingbird Bioscience. Focusing on the discovery and development of new breakthrough therapies, Hummingbird Bioscience closed the $ 25 million extended B Series financing tour led by SK Holdings.
Other companies participating in the investment tour were announced as SEEDS Capital, the investment arm of Heritas Capital and Enterprise Singapore. Among the previous investors of the venture are Mirae Asset Venture Investment and GNTech Venture Capital. Hummingbird Bioscience announced that it will use its new investment to accelerate the development of clinical trials and strengthen its scientific research and development capabilities.
Hummingbird Bioscience aims to find cancer treatment. Founded in 2015, the company uses system biology to develop a rational antibody discovery platform that can accurately identify key targets in diseased cells. Hummingbird develops computational guided platforms to discover and create biotherapeutics. To achieve these goals, it designs molecules and prevents cell proteins from multiplying. Let us also underline that anti-VISTA and anti-HER3 antibodies significantly reduce the size of tumor samples in laboratory tests.
In addition to its previous investments, Hummingbird Bioscience also received product development grants from Cancer Research UK and Amgen and the Cancer Prevention and Research Institute of Texas. Hummingbird Bioscience, headquartered in Singapore, also operates in Houston, Texas and San Francisco.
